---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-24-000049"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2024-07-15T23:59:59+00:00"
generated_at: "2026-05-31T20:48:00.937823+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics raises $30M from Ridgeback Capital in PIPE at $19/share

## Summary
- PIPE financing of $30M with Ridgeback Capital at $19.00 per share; expected to close July 17, 2024.
- Proceeds to support regulatory and commercial launch activities for LNZ100, a presbyopia eye drop.
- NDA submission for LNZ100 planned mid-2024; Phase 3 CLARITY data cited as strong.
- Ridgeback Capital founder Dr. Wayne Holman expressed support; shares unregistered with resale registration to be filed.
- Existing cash plus PIPE proceeds to fund pre-commercial and potential launch activities.

## SEC filing metadata
- accession: 0001815776-24-000049
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2024-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000049/0001815776-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577624000049/lenz-20240714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-24-000049
- JSON: https://secwatch.observer/filing/0001815776-24-000049.json
- Plain text: https://secwatch.observer/filing/0001815776-24-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.